CDC AdCom recommends Abrysvo to prevent RSV in infants

The US Centers for Disease Control and Prevention’s (CDC) vaccine advisory committee (ACIP) on Friday afternoon voted 11-1 to recommend US pharma giant Pfizer’s (NYSE: PFW) Abrysvo, [respiratory syncytial virus vaccine], for pregnant women at 32 to 36 weeks of gestation to prevent RSV in their infants.

This is the first-ever fall season in which eligible individuals can receive Pfizer vaccines to help protect against RSV, COVID-19, and pneumococcal pneumonia, the company noted.

“This is another new tool we can use this fall and winter to help protect lives,” said CDC director Dr Mandy Cohen, adding: “I encourage parents to talk to their doctors about how to protect their little ones against serious RSV illness, using either a vaccine given during pregnancy, or an RSV immunization given to your baby after birth.”